2018). Similarly, the concentrations of other molecules from the chitinase family (e.g., chitotriosidase, acidic mammalian chitinase, chitinase 3‐like protein 2) are increased in the brains of AD patients (Sanfilippo et al. 2016). In the recently published study by Pase et al. (2024), CHI3L1 was considered a nonspecific prognostic biomarker of cognitive impairment independent of AD processes. As with other biomarkers of neurodegeneration, CHI3L1 is considered a potential therapeutic target for future trials (Yu et al. 2024). This evidence concerns the gene CHI3L1 and Cognitive impairment.